Table 3.
Summary association results for rs138213197[T] in HOXB13 and prostate cancer
| Frequency |
||||||
|---|---|---|---|---|---|---|
| Study population |
Cases (n) |
Control s (n) |
Cases | Control s |
OR (95% CI) | P value |
| Iceland | 4,537 | 54,444 | 0.0029 | 0.00080 | 3.67 (1.71, 7.90) | 8.8×10−4 |
| Chicago | 1,982 | 1,260 | 0.0058 | 0.00040 | 14.70 (3.59, 60.14) | 1.8×10−4 |
| Spain | 716 | 1,692 | 0.00070 | 0.0 | inf | 0.30 |
| The Netherlands | 1,520 | 1,916 | 0.015 | 0.0021 | 7.51 (3.99, 14.11) | 3.9×10−10 |
| Romania | 722 | 857 | 0.0014 | 0.0012 | 1.19 (0.00, inf) | 1.0 |
| UK | 511 | 1,825 | 0.012 | 0.00082 | 14.44 (4.74, 44.03) | 2.7×10−6 |
| All excl. Iceland | 5,451 | 7,550 | - | 0.00089 | 9.41 (5.66, 15.64) | 5.1×10−18 |
| All combined | 9,988 | 61,994 | - | 0.00088 | 7.06 (4.62, 10.78) | 1.5×10−19 |
| Phet = 0.36 | I2 = 8.6 | |||||
All P values shown are two-sided. Shown are the corresponding numbers of cases and controls (n), allelic frequencies of variants in affected and control individuals, the allelic odds-ratio (OR) with 95% confidence interval (95% CI) and P value. Also shown are the P-values for the heterogeneity of the ORs (Phet) for all study groups as well as I2 which lies between 0% and 100% and describes the proportion of total variation in study estimates that is due to heterogeneity. For the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, while the OR and the P value were estimated using the Mantel-Haenszel model. Of the Icelandic cases, 2,315 patients had been genotyped using one of the Illumina chips, and 2,222 additional patients had at least partial data based on family based imputation. Of the Icelandic controls 27,780 were imputed based on chip-genotypes and 26,664 were family based imputed. All non-Icelandic replication samples are directly genotyped.